Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-08-08 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思公司章程
Governance Information Classification · 100% confidence The document is titled as the "Company Articles of Association" (公司章程) for Hangzhou AGS MedTech Co Ltd. It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, financial accounting, profit distribution, and other governance matters. It references relevant laws such as the Company Law and Securities Law of China, and includes sections on shareholder meetings, share issuance, share transfer, board responsibilities, and internal audit. The document is a comprehensive governance document that sets out the internal rules and regulations of the company rather than a financial report, announcement, or other filing type. Therefore, it fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is the full governance document, not an announcement or summary. Hence, the classification is CGR with high confidence.
2024-08-08 Chinese
安杰思关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Hangzhou Anjiese Medical Technology Co., Ltd. regarding the delay of certain fundraising investment projects. It details the original and adjusted dates for project completion, reasons for the delay, and confirms that the use of funds and project scope remain unchanged. The document includes references to regulatory approvals and compliance with securities regulations. The length is 4295 characters, which is relatively short and the document is primarily an announcement about the delay of a fundraising project rather than a full financial report or detailed financial data. It does not contain financial statements or comprehensive financial analysis. Therefore, it is best classified as a Capital/Financing Update (CAP) because it updates shareholders and the market on the status of capital raised and its use, specifically the delay in the use of raised funds for a project.
2024-08-08 Chinese
杭州安杰思医学科技股份有限公司2023年限制性股票激励计划调整及预留部分授予事项的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2023 restricted stock incentive plan of Hangzhou Anjiesi Medical Technology Co., Ltd. It discusses the approval, authorization, price and quantity adjustments, and reserved grants related to the stock incentive plan. The content is focused on legal compliance and the specifics of the stock incentive plan rather than financial results or management changes. It is not an announcement of a report, nor a financial report itself. It is a legal opinion related to a capital/incentive plan, which fits best under Capital/Financing Update (CAP) as it deals with stock incentive plan adjustments and grants, which are financing-related activities.
2024-08-08 Chinese
安杰思关于调整2023年限制性股票激励计划相关事项的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding adjustments to the 2023 restricted stock incentive plan of Hangzhou Anjiesi Medical Technology Co., Ltd. It details board and supervisory meetings, approvals, legal opinions, and adjustments to stock grant prices and quantities. The content focuses on corporate governance and management decisions related to stock incentives rather than financial results or earnings. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement of management decisions about stock incentive plans, which fits best under Board/Management Information (MANG). The document length is about 4048 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is MANG with high confidence.
2024-08-08 Chinese
安杰思2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '2024 年半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full semi-annual report for comprehensive details. The length of the document (7584 characters) and the presence of substantive financial data and analysis indicate this is a financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but contains actual financial data and analysis for the half-year period. H1 2024
2024-08-08 Chinese
安杰思关于公司2024年度提质增效重回报专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is a half-year assessment report on the company's 2024 quality improvement and return action plan. It contains detailed operational, R&D, financial, and governance information for the first half of 2024, including financial figures, investment in R&D, shareholder returns, and governance updates. The document is comprehensive and covers substantive financial and operational data for a period shorter than a full fiscal year. It is not merely an announcement or a brief summary but a detailed report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 4681 characters, which is sufficient for a substantive report rather than a brief announcement. H1 2024
2024-08-08 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.